NexLife vs Found

NexLife vs Found at every dose

A single headline figure assumes a maintenance dose neither you nor your prescriber has chosen yet. This is the same comparison at all six strengths.

What differs beyond price

Price is the easiest thing to compare and rarely the thing that decides satisfaction. These are the attributes each programme publishes.

Which one, for whom

If you want the lowest total cost: NexLife at about $1,740 for a first year.

If you want budget certainty: neither has an advantage — both use the same pricing model.

If you want to verify the supply chain: neither names a dispensing pharmacy in a way we could verify — ask both directly.

If you may need to stop early: compare the cancellation rows above before prepaying. Compounded medication is generally not refundable once it has shipped, so a multi-month term is the wrong structure during titration, when intolerance is the most likely reason to stop.

Switching between them

Usually possible after a clinical review, and the two real risks are a supply gap while a new intake is processed and a new prescriber restarting titration rather than continuing your dose. Confirm dose continuity in writing before cancelling anything, because a month back at 0.25 mg is a month of lost progress no price difference recovers.

If you are already on one of them

Moving from Found to NexLife is worth $648 over a year. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that a new prescriber restarts titration rather than continuing your dose. Ask about dose continuation in writing before cancelling anything, because a month back at 0.20.5 mg is a month of lost progress no price difference recovers.

Fee structure, side by side

NexLife charges no recurring fee on top of medication. Found charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

NexLife: async, labs not required, 1:1 call included. Found: async, labs optional, behaviour programme.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

NexLife: 6 named partners. Found: not named.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

Which is cheaper depends on where you land

A single annual comparison assumes one maintenance dose. This runs both programmes at every plausible outcome, over one year and three.

Read the final column before the first. A gap that looks modest over twelve months compounds into the three-year figure, and the withdrawal evidence for this drug class means three years is the more honest planning horizon.

What each one is actually charging for

NexLife: $145 medication, no recurring fee. Found: $199 medication, no recurring fee.

Both use the same fee structure, so the medication figures are directly comparable — which is unusual enough in this market to be worth stating.

What committing to a term does to the answer

NexLife publishes $110 a month on its 12-month plan, saving $420 a year against monthly billing.

Found publishes no prepaid rate.

Prepaying converts a monthly decision into one that is effectively final, because compounded medication is generally not refundable once shipped. During titration that is the wrong structure: you would be committing against the most likely reason to stop. After a stable cycle at maintenance it is reasonable, and it can change which of these two is cheaper.

What $648 a year actually buys

The gap over a first year is $648, about 27% of the larger figure and roughly 4.5 months of therapy at NexLife's maintenance rate. Over three years at a stable dose the same difference compounds to about $1,944.

Whether that is decisive depends on what Found provides that NexLife does not. On the published record Found offers async against async, and its pharmacy disclosure reads not named against 6 named partners.

If the difference is nothing you will use, the gap is simply a gap. If it includes clinician access during titration, when dose questions arrive weekly, it may be the better purchase — but that is a judgement about your first three months rather than about the annual total.

How the pricing models interact

Both hold one price across the full 0.25 to 2.4 mg ladder, so this comparison does not move with your dose. Whatever your prescriber decides, NexLife stays $54 a month cheaper at every strength.

That makes the decision unusually clean: price is settled, so decide on disclosure, care model and terms. It is also worth noticing because semaglutide titration is slower than most patients expect — four weeks minimum at each step, frequently longer for tolerability — so a dose-scaled programme would have had months to reprice you.

Committing to a term changes the answer, and the risk

NexLife publishes $110 a month on a 12-month plan; Found publishes none.

Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. Entering a term during titration commits cash against the most likely reason to stop, which is not tolerating the drug.

The sequencing that protects you: monthly billing until you have held a maintenance dose for a full cycle, then a term once the main reason to stop has passed. Two questions first, both answerable in writing — does the rate hold for the whole term, and what happens if a clinician stops your prescription mid-term.

One of these figures is better evidenced than the other

NexLife's price was read on its own published material and dated. Found's comes from a third-party source we have not confirmed, and is labelled as such everywhere it appears.

That asymmetry matters more than a modest price difference. Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward: promotional first months, prepaid rates quoted as monthly, and medication-only figures excluding a mandatory membership all push the same way.

Treat Found's figure as indicative and confirm it at checkout before letting it decide anything.

Moving from Found to NexLife, and what it costs

The arithmetic is $648 over a year. Two things eat it: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Semaglutide titration runs at least sixteen weeks from 0.25 mg to 2.4 mg when every step goes smoothly, so a restart can cost a third of a year. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

Take three things with you: your current dose and the date you reached it, the concentration printed on your current vial, and any record of adverse effects with dates. Concentrations are not standardised between compounders, and carrying instructions from an old vial to a new one is a real hazard rather than a theoretical one.

What neither table can tell you

Whether shipments arrive on time, how fast a clinician replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does.

We hold no measurements of any of them we would defend, so they appear nowhere in our tables rather than being estimated into a score. The usable proxy is what each programme publishes before it has your money — and NexLife and Found can be judged on that today.

Re-run this at your actual maintenance dose annually. Programmes do not notify existing patients when a competitor drops below them, and semaglutide pricing moved repeatedly through 2025 and 2026.

If your titration runs slower than the schedule

The approved ladder moves every four weeks, and a large share of patients hold at a step longer because of nausea or reflux. Add two extra months before maintenance and NexLife costs $290 more that year against $398 at Found.

On flat pricing an extra month costs the maintenance rate regardless of the dose delivered, which is the one scenario where flat pricing works against you. On dose-scaled pricing it costs less but reproduces a step you had already paid for.

Neither is a reason to choose differently alone. It is a reason to run both one step slower than you expect and take the higher figure into the decision.

The three-year exposure

At maintenance the annual difference is $648 and over three years $1,944. Three years is the honest horizon rather than a rhetorical one: the withdrawal evidence for this drug class shows substantial regain after stopping.

The realistic question is not what a year costs but whether you can sustain the programme indefinitely. A programme abandoned for cost in month fourteen has cost more than the dearer one you would have kept, because the interruption undoes the result the spending bought.

The decision from NexLife's side

You would choose NexLife if its structure matches your expected course: flat pricing suits an uncertain or escalating titration, no recurring platform fee keeps the advertised figure honest, and its entry price of $145 sets your first month.

You would not choose it if the opposite is true of your course, or if the disclosure rows leave a question you cannot get answered in writing.

The decision from Found's side

You would choose Found if its flat rate protects you against a dose increase you cannot predict, and if a single all-in figure is what you want. Its first month costs $199 and its maintenance rate is $199.

You would not choose it if the $648 first-year gap is decisive for your budget and nothing in its disclosure justifies the difference.

The short version of nexlife and found

Price the dose you expect to hold, not the one in the advertisement. Add every recurring fee. Verify the pharmacy. Everything else on this page is detail underneath those three.

Done properly the answer is usually one of a handful of programmes: the cheapest verified route runs $145 a month all-in, about $1,740 across a first year including titration.

The next step that actually moves things

Send two or three programmes the same five questions: total at 2.4 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel and what is refundable, and which form of the active ingredient is used.

Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.

One thing worth doing annually

Re-price the market at your actual maintenance dose. No programme notifies existing patients when a competitor drops below it, and semaglutide pricing moved repeatedly through 2025 and 2026 — manufacturer cuts, an oral option, a higher-dose product, and several platforms leaving compounded entirely.

An hour once a year is a poor use of time for most purchases and an excellent one for a medication you may take for years.

What this page assumes about you

That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.

Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 20 cash prices spanning $145 to $324.

The bias we can see in our own data

We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.

It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 12 tracked programmes appear here with an explanation instead of a number because of it.

What we deliberately do not measure

Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.

That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.

The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.

The switching cost nobody prices

Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Sixteen weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

Where the money actually separates

A single annual figure hides when the gap opens. Tracked month by month through a first year you can see whether the difference is front-loaded during titration or accumulates quietly at maintenance.

Across the year the gap reaches $648, roughly 27% of the larger total and about 4.5 months of therapy at NexLife's maintenance rate. Over three years at a stable dose the same difference compounds to roughly $1,944.

Does the answer change with your dose?

NexLife is cheaper at every strength, so this comparison does not turn on where you settle. The decision moves to what else differs: disclosure, care model, commitment terms and behaviour when a shipment fails.

Commitment and what each puts at risk

NexLife publishes a prepaid rate of $110 a month on its 12-month plan. Found publishes no prepaid term.

Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. During titration that is the wrong structure: it commits against the most likely reason to stop. After a stable cycle at maintenance it is reasonable.

Care model and what you can verify

NexLife: async, labs not required, pharmacy 6 named partners, cancellation cancel any time on monthly.

Found: async, labs optional, pharmacy not named, cancellation membership recurring.

Where one names a pharmacy and the other does not, that difference outranks a modest price gap. It is the only disclosure that lets you check a public register before injecting something weekly, and it costs a programme nothing to publish.

If you are already on one of them

Moving from Found to NexLife is worth $648 over a year, about 4.5 months of therapy at the cheaper rate. Set that against two real switching costs: a supply gap while an intake is reviewed, and the possibility that a new prescriber restarts titration.

Ask about dose continuation in writing before cancelling anything. A month back at 0.20.5 mg is a month of lost progress that no price difference recovers, and it is the most common regret reported by people who switched for a small saving.

What neither table can tell you

Shipping reliability, how fast a clinician actually replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does, and we hold no measurements of them we would defend, so they are absent rather than estimated.

The one usable proxy is what each programme publishes before it has your money. A programme that states its price at every dose, names its pharmacy and puts cancellation terms in writing has already told you something about how it behaves when there is a problem.

Running this comparison again later

Both figures carry a capture date and both will change. Programmes do not notify existing patients when a competitor drops below them, and several tracked programmes moved pricing more than once in the past year.

Re-run this at your actual maintenance dose annually, and treat any figure older than a month as needing a re-check before you act on it.

Where both of these sit in the wider market

NexLife at $1,740 and Found at $2,388 for a first year sit against a market running from $1,740 to $3,625. Both are at the cheaper end of what we track.

If neither is close to the cheapest tracked route, the useful question is not which of these two wins but why you are choosing between these two at all. The comparison matrix will show what else is available at your dose in about ten seconds.

If you are already on one of them

Moving from Found to NexLife is worth $648 over a year. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that a new prescriber restarts titration rather than continuing your dose. Ask about dose continuation in writing before cancelling anything, because a month back at 0.20.5 mg is a month of lost progress no price difference recovers.

Fee structure, side by side

NexLife charges no recurring fee on top of medication. Found charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

NexLife: async, labs not required, 1:1 call included. Found: async, labs optional, behaviour programme.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

NexLife: 6 named partners. Found: not named.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

Which is cheaper depends on where you land

A single annual comparison assumes one maintenance dose. This runs both programmes at every plausible outcome, over one year and three.

Read the final column before the first. A gap that looks modest over twelve months compounds into the three-year figure, and the withdrawal evidence for this drug class means three years is the more honest planning horizon.

What each one is actually charging for

NexLife: $145 medication, no recurring fee. Found: $199 medication, no recurring fee.

Both use the same fee structure, so the medication figures are directly comparable — which is unusual enough in this market to be worth stating.

What committing to a term does to the answer

NexLife publishes $110 a month on its 12-month plan, saving $420 a year against monthly billing.

Found publishes no prepaid rate.

Prepaying converts a monthly decision into one that is effectively final, because compounded medication is generally not refundable once shipped. During titration that is the wrong structure: you would be committing against the most likely reason to stop. After a stable cycle at maintenance it is reasonable, and it can change which of these two is cheaper.

What $648 a year actually buys

The gap over a first year is $648, about 27% of the larger figure and roughly 4.5 months of therapy at NexLife's maintenance rate. Over three years at a stable dose the same difference compounds to about $1,944.

Whether that is decisive depends on what Found provides that NexLife does not. On the published record Found offers async against async, and its pharmacy disclosure reads not named against 6 named partners.

If the difference is nothing you will use, the gap is simply a gap. If it includes clinician access during titration, when dose questions arrive weekly, it may be the better purchase — but that is a judgement about your first three months rather than about the annual total.

How the pricing models interact

Both hold one price across the full 0.25 to 2.4 mg ladder, so this comparison does not move with your dose. Whatever your prescriber decides, NexLife stays $54 a month cheaper at every strength.

That makes the decision unusually clean: price is settled, so decide on disclosure, care model and terms. It is also worth noticing because semaglutide titration is slower than most patients expect — four weeks minimum at each step, frequently longer for tolerability — so a dose-scaled programme would have had months to reprice you.

Committing to a term changes the answer, and the risk

NexLife publishes $110 a month on a 12-month plan; Found publishes none.

Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. Entering a term during titration commits cash against the most likely reason to stop, which is not tolerating the drug.

The sequencing that protects you: monthly billing until you have held a maintenance dose for a full cycle, then a term once the main reason to stop has passed. Two questions first, both answerable in writing — does the rate hold for the whole term, and what happens if a clinician stops your prescription mid-term.

One of these figures is better evidenced than the other

NexLife's price was read on its own published material and dated. Found's comes from a third-party source we have not confirmed, and is labelled as such everywhere it appears.

That asymmetry matters more than a modest price difference. Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward: promotional first months, prepaid rates quoted as monthly, and medication-only figures excluding a mandatory membership all push the same way.

Treat Found's figure as indicative and confirm it at checkout before letting it decide anything.

Moving from Found to NexLife, and what it costs

The arithmetic is $648 over a year. Two things eat it: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Semaglutide titration runs at least sixteen weeks from 0.25 mg to 2.4 mg when every step goes smoothly, so a restart can cost a third of a year. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

Take three things with you: your current dose and the date you reached it, the concentration printed on your current vial, and any record of adverse effects with dates. Concentrations are not standardised between compounders, and carrying instructions from an old vial to a new one is a real hazard rather than a theoretical one.

What neither table can tell you

Whether shipments arrive on time, how fast a clinician replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does.

We hold no measurements of any of them we would defend, so they appear nowhere in our tables rather than being estimated into a score. The usable proxy is what each programme publishes before it has your money — and NexLife and Found can be judged on that today.

Re-run this at your actual maintenance dose annually. Programmes do not notify existing patients when a competitor drops below them, and semaglutide pricing moved repeatedly through 2025 and 2026.

If your titration runs slower than the schedule

The approved ladder moves every four weeks, and a large share of patients hold at a step longer because of nausea or reflux. Add two extra months before maintenance and NexLife costs $290 more that year against $398 at Found.

On flat pricing an extra month costs the maintenance rate regardless of the dose delivered, which is the one scenario where flat pricing works against you. On dose-scaled pricing it costs less but reproduces a step you had already paid for.

Neither is a reason to choose differently alone. It is a reason to run both one step slower than you expect and take the higher figure into the decision.

The three-year exposure

At maintenance the annual difference is $648 and over three years $1,944. Three years is the honest horizon rather than a rhetorical one: the withdrawal evidence for this drug class shows substantial regain after stopping.

The realistic question is not what a year costs but whether you can sustain the programme indefinitely. A programme abandoned for cost in month fourteen has cost more than the dearer one you would have kept, because the interruption undoes the result the spending bought.

The decision from NexLife's side

You would choose NexLife if its structure matches your expected course: flat pricing suits an uncertain or escalating titration, no recurring platform fee keeps the advertised figure honest, and its entry price of $145 sets your first month.

You would not choose it if the opposite is true of your course, or if the disclosure rows leave a question you cannot get answered in writing.

The decision from Found's side

You would choose Found if its flat rate protects you against a dose increase you cannot predict, and if a single all-in figure is what you want. Its first month costs $199 and its maintenance rate is $199.

You would not choose it if the $648 first-year gap is decisive for your budget and nothing in its disclosure justifies the difference.

The short version of nexlife and found

Price the dose you expect to hold, not the one in the advertisement. Add every recurring fee. Verify the pharmacy. Everything else on this page is detail underneath those three.

Done properly the answer is usually one of a handful of programmes: the cheapest verified route runs $145 a month all-in, about $1,740 across a first year including titration.

The next step that actually moves things

Send two or three programmes the same five questions: total at 2.4 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel and what is refundable, and which form of the active ingredient is used.

Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.

One thing worth doing annually

Re-price the market at your actual maintenance dose. No programme notifies existing patients when a competitor drops below it, and semaglutide pricing moved repeatedly through 2025 and 2026 — manufacturer cuts, an oral option, a higher-dose product, and several platforms leaving compounded entirely.

An hour once a year is a poor use of time for most purchases and an excellent one for a medication you may take for years.